Medical Health & Life Science Research News

New report shares details about the gene therapy for ovarian cancer industry

Medical Market Research

The latest trend gaining momentum in the market is the adoption of replacement gene therapy. Ovarian cancer has the lowest survival rate among all the other types of gynecological cancers.

- Advertising -

Epithelial ovarian cancer (EOC) is the most common ovarian cancer witnessed among patients.

Report at www.reportsnreports.com/contacts/r…spx?name=1286829.

- Advertising -

Players in the ovarian cancer immunotherapies market have come up with few chemotherapy products that are commercially successful. However, chemotherapy can cause blood-related complications by damaging the blood-producing cells of the bone marrow.

This in turn is fueling the popularity of gene therapy which is expected to be one of the biggest paradigm shifts in pharmacology.

Major key players in the gene therapy for ovarian cancer: Takara Bio, VBL, Therapeutics, Targovax, CELSION, Lokon Pharma, SiBiono GeneTech, and Advantagene

Report at www.reportsnreports.com/contacts/.aspx?name=1286829.

Ovarian cancer occurs and arises from several types of cells within the ovary, and it has the lowest survival rate of all gynecological cancers. Among many types, epithelial ovarian cancer (EOC) is the most common ovarian cancer, whereas ovarian low malignant potential tumor (OLMPT), germ cell tumor, and stromal ovarian tumor are some of the less common types.

It is the seventh most common cancer in women globally and 18th most common cancer overall. The ovarian cancer immunotherapies market has already got some commercially successful chemotherapy products.

However, chemotherapy often involves a combination of two or more drugs, given intravenously every 3-4 weeks, and mostly associated with long-lasting side/adverse effects. Various studies have shown that chemotherapy can damage the blood-producing cells of the bone marrow, resulting in blood-related complications.

Report at www.reportsnreports.com/.aspx?name=1286829.

Key questions answered in this report

What will the market size be in 2022 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

Few Points from List of Exhibits Provided in Global Gene Therapy for Ovarian Cancer- A Pipeline Analysis:

Exhibit 1: Drug Approval Process by Us Fda

Exhibit 2: Pipeline Landscape

Exhibit 3: Pipeline Molecules by Vendors

Exhibit 4: Pipeline Molecules by Numbers

Exhibit 5: Pipeline Molecules by Percentage

Exhibit 6: Overview: P53 Gene Therapy

Exhibit 7: Clinical Trials Description of P53 Gene

Exhibit 8: Overview: Ofranergene Obadenovec

Exhibit 9: Clinical Trials Description of Ofranergene Obadenovec

Exhibit 10: Overview: Gen-1

Exhibit 11: Clinical Trials Description of Gen-1

Exhibit 12: Overview: Load703

Exhibit 13: Clinical Trials Description of Load703

Exhibit 14: Overview: Oncos-102

Exhibit 15: Clinical Trials Description of Oncos-102

 

News From

ReportsnReports - Industry Trends & ForecastsReportsnReports
Category: Market Research Publishers and RetailersCompany about: ReportsnReports.com provides market research reports to industries, individuals and organizations with an objective of helping them in their decision-making process. Our library of 400,000+ industry & country research reports covers 5000+ micro markets. Email us at This email address is being protected from spambots. You need JavaScript enabled to view it..
This email address is being protected from spambots. You need JavaScript enabled to view it.